Drug: lovastatin

The Supreme Court of Canada dismissed Merck’s application for leave to appeal, with costs to Apotex. The case summary prepared by the Court indicates that the issue for which leave was sought was whether the discretion the Federal Court has to hear a moot case means that the Court has the power to grant a remedy, although the remedy is impossible to grant because the case is moot. The case related to an action for damages pursuant to section 8 of the NOC Regulations.